

Alfacalcidol**Section**

Medicines for endocrine disorders

- Oral > Liquid: 2 µg per mL
- Oral > Solid > capsule: 0.25 µg; 1 µg

Indications

Chronic kidney disease, stage unspecified

Disorders of vitamin D metabolism or transport

Beinaglutide**Section**

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Bromocriptine**Section**

Medicines for disorders of the pituitary hormone system

Indications

Therapeutic equivalent to [cabergoline](#) for

Other specified benign neoplasm of endocrine glands

Cabergoline**Section**

Medicines for disorders of the pituitary hormone system

- Oral > Solid > tablet: 0.5 mg; 1 mg

Indications

Other specified benign neoplasm of endocrine glands

Calcitriol**Section**

Medicines for endocrine disorders

- Oral > Solid > capsule: 0.25 µg; 0.5 µg

Indications

Chronic kidney disease, stage unspecified

Disorders of vitamin D metabolism or transport

Canagliflozin**Section**

Hypoglycaemic agents

Indications

Therapeutic equivalent to [empagliflozin](#) for

Type 2 diabetes mellitus

Carbimazole

Section

Thyroid hormones and antithyroid medicines

Indications

Therapeutic equivalent to [methimazole](#) for

Thyrotoxicosis

Dapagliflozin

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [empagliflozin](#) for

Type 2 diabetes mellitus

Diazoxide

Section

Medicines for hypoglycaemia

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 50 mg

Indications

Persistent hyperinsulinaemic hypoglycaemia of infancy

Dulaglutide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Therapeutic equivalent to [semaglutide](#) for

Type 2 diabetes mellitus

Empagliflozin

Section

Hypoglycaemic agents

- Oral > Solid: 10 mg; 25 mg

Indications

Type 2 diabetes mellitus

Estradiol

Section

Estrogens

- Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg

Indications

Hypopituitarism

Gonadotropin deficiency

Turner syndrome

Exenatide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Fludrocortisone

Section

Adrenal hormones and synthetic substitutes

- Oral > Liquid: 100 µg per mL
- Oral > Solid > tablet: 100 µg (acetate)

Indications

Adrenocortical insufficiency

Glibenclamide

Section

Hypoglycaemic agents

- Oral > Solid: 5 mg; 2.5 mg

Indications

Type 2 diabetes mellitus

Gliclazide

Section

Hypoglycaemic agents

- Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release

Indications

Type 2 diabetes mellitus

Glucagon

Section

Medicines for hypoglycaemia

- Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent

Indications

Hypoglycaemia in the context of diabetes

Hydrocortisone

Section

Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 5 mg; 10 mg; 20 mg
- Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule

Indications

Adrenocortical insufficiency

Insulin (analogue, long-acting)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution

Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

Insulin (analogue, rapid-acting)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen

Indications

Type 1 diabetes mellitus

Type 2 diabetes mellitus

Insulin (human, intermediate-acting)

Section

Insulins

- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin

Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

Insulin (human, short-acting)

Section

Insulins

- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution

Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

Insulin analogues

Section

Insulins

- Not specified

Indications

Type 2 diabetes mellitus

Type 1 diabetes mellitus

Insulin aspart

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 2 diabetes mellitus

Insulin degludec

Section

Insulins

- Parenteral > General injections > SC: 100 units per mL

Indications

Therapeutic equivalent to [insulin glargine](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 2 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 1 diabetes mellitus

Insulin detemir

Section

Insulins

Therapeutic equivalent to [insulin glargine](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 2 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 1 diabetes mellitus

Insulin glargine

Section

Insulins

- Parenteral > General injections > SC: 100 units per mL

Indications

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 2 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for

Type 1 diabetes mellitus

Insulin glulisine

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 2 diabetes mellitus

Insulin lispro

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 1 diabetes mellitus

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

Type 2 diabetes mellitus

Iodine + potassium iodide (Lugol's solution)

Section

Thyroid hormones and antithyroid medicines

- Oral > Liquid: 5% w/v + 10% w/v (aqueous)

Indications

Thyrotoxicosis

Ketoconazole

Section

Medicines for endocrine disorders

- Oral > Solid > tablet: 200 mg

Indications

Cushing syndrome

Levothyroxine

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)

Indications

Hypothyroidism

Liraglutide

Section

Medicines for endocrine disorders

- Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen

Hypoglycaemic agents

Indications

Obesity

Therapeutic equivalent to [semaglutide](#) for

Obesity

Therapeutic equivalent to [semaglutide](#) for

Type 2 diabetes mellitus

Medroxyprogesterone acetate

Section

Progestogens

- Oral > Solid: 5 mg

Indications

Excessive menstruation with irregular cycle

Metformin

Section

Hypoglycaemic agents

- Oral > Solid: 500 mg (hydrochloride)

Indications

Type 2 diabetes mellitus

Methimazole

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 5 mg; 10 mg

Indications

Thyrotoxicosis

Norethisterone

Section

Progestogens

- Oral > Solid: 5 mg

Indications

Excessive menstruation with irregular cycle

Therapeutic equivalent to [medroxyprogesterone acetate](#) for

Excessive menstruation with irregular cycle

Octreotide

Section

Medicines for disorders of the pituitary hormone system

- Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
- Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)

Indications

Acromegaly or pituitary gigantism

Phosphorus

Section

Medicines for endocrine disorders

- Oral > Other: 500 mg in sachet (elemental phosphorus) granules
- Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)

Indications

Hypophosphataemic rickets

Potassium iodide

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 65 mg (scored)

Indications

Thyrotoxicosis

Prednisolone

Section	Indications
Adrenal hormones and synthetic substitutes Oral > Solid > tablet: 1 mg	Adrenocortical insufficiency

Prednisone

Section	Indications
Adrenal hormones and synthetic substitutes Oral > Solid > tablet: 1 mg	Therapeutic equivalent to prednisolone for Adrenocortical insufficiency

Propylthiouracil

Section	Indications
Thyroid hormones and antithyroid medicines Oral > Solid: 50 mg	Thyrotoxicosis

Semaglutide

Section	Indications
Hypoglycaemic agents - Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution - Oral > Solid > tablet: 3 mg - Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL	Obesity Type 2 diabetes mellitus

Simvastatin

Section	Indications
Medicines for endocrine disorders Oral > Solid: 20 mg	Polycystic ovary syndrome

Somatropin

Section	Indications
Medicines for endocrine disorders Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge	Hypoglycaemia without associated diabetes

Testosterone

Section	Indications
Androgens Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)	Testicular dysfunction or testosterone-related disorders

Tirzepatide

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Therapeutic equivalent to [semaglutide](#) for

Type 2 diabetes mellitus

Tolbutamide

Section

Hypoglycaemic agents

- Oral > Solid: 500 mg

Indications

Type 2 diabetes mellitus

Zoledronic acid

Section

Medicines for endocrine disorders

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

Osteogenesis imperfecta